| 排名 | 分析师 | 机构 | 行业 | 年度收益率 | 6个月收益率 | 3个月收益率 | 正收益比例 | 成分股数量 | 历史最大跌幅 | 更新日期 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 赵海春 | 国金证券 | 医药生物 | 234.75% | -11.98% | 5.27% | -25.00% | 1 | -61.07% | 2015-12-31 |
| 2 | 盛丽华 | 中邮证券 | 医药生物 | 94.21% | 7.78% | -2.95% | -35.45% | 25 | -68.83% | 2020-12-31 |
| 3 | 刘浩 | 华创证券 | 医药生物 | 87.98% | 14.58% | -7.53% | 20.00% | 3 | -47.33% | 2025-12-05 |
| 4 | 王睿哲 | 群益证券 | 医药生物 | 81.38% | 22.34% | 5.37% | -6.21% | 10 | -42.83% | 2020-12-31 |
| 5 | 胡晨曦 | 长城国瑞证券 | 医药生物 | 80.66% | 4.58% | -8.96% | 10.00% | 7 | -36.35% | 2025-12-05 |
| 6 | 罗佳荣 | 广发证券 | 医药生物 | 72.45% | 26.46% | 6.90% | -2.15% | 12 | -76.45% | 2019-12-31 |
| 7 | 李安飞 | 中信证券 | 医药生物 | 65.70% | 9.32% | 0.00% | -2.86% | 0 | -56.96% | 2025-12-05 |
| 8 | 刘鹏 | 长城证券 | 医药生物 | 64.40% | -0.20% | 6.37% | -9.22% | 14 | -72.34% | 2019-12-31 |
| 9 | 马帅 | 国投证券 | 医药生物 | 61.80% | 16.06% | 3.40% | -13.73% | 28 | -79.20% | 2019-12-31 |
| 10 | 黄婧婧 | 万联证券 | 医药生物 | 36.72% | 1.56% | 24.85% | -37.50% | 2 | -47.28% | 2022-12-30 |
| 11 | 李华云 | 长城证券 | 医药生物 | 34.76% | 29.04% | 17.21% | -7.69% | 7 | -33.32% | 2023-12-29 |
| 12 | 彭思宇 | 国信证券 | 医药生物 | 34.59% | 30.85% | 24.25% | -33.33% | 4 | -39.78% | 2026-09-16 |
| 13 | 余玉君 | 申万宏源 | 医药生物 | 29.76% | 32.67% | 46.24% | -21.74% | 2 | -38.76% | 2026-08-20 |
| 14 | 吴号 | 财信证券 | 医药生物 | 27.61% | -7.09% | 15.01% | -47.37% | 10 | -60.39% | 2022-12-30 |
| 15 | 夏禹 | 国联民生 | 医药生物 | 26.51% | 9.98% | 10.38% | 16.13% | 8 | -52.01% | 2022-12-30 |
| 16 | 俞家宁 | 华鑫证券 | 医药生物 | 24.47% | 24.47% | 8.92% | -33.33% | 13 | -45.82% | 2023-12-29 |
| 17 | 李明 | 国海证券 | 医药生物 | 23.34% | 0.52% | 20.61% | 27.27% | 0 | -19.27% | 2026-08-04 |
| 18 | 黎一江 | 光大证券 | 医药生物 | 18.80% | -7.49% | 2.62% | -33.33% | 2 | -45.51% | 2023-12-29 |
| 19 | 胡博新 | 华鑫证券 | 医药生物 | 12.66% | 19.67% | 6.52% | -6.72% | 14 | -51.98% | 2026-01-07 |
| 20 | 唐爱金 | 信达证券 | 医药生物 | 11.21% | 16.13% | 2.72% | -15.38% | 13 | -63.95% | 2026-01-07 |